Communiqués Arrowhead Pharmaceuticals, Inc.

Actions

ARWR

US04280A1007

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:55:33 30/09/2026			Varia. 5j.	Varia. 1 janv.
65,98 ^USD	-0,40%		-1,81%	-0,97%

16/09	Transcript : Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 09:00 AM
15/09	Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM

Communiqués

29/09	Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies	BU
15/09	Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	BU
03/09	Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences	BU
30/08	Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia	BU
24/08	Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress	BU
18/08	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO(R) (plozasiran) as a New Treatment Option to Reduce Triglycerides	AQ
18/08	Arrowhead Pharmaceuticals - People Living with Familial Chylomicronaemia Syndrome in Germany Have Access to REDEMPLO as a New Treatment Option to Reduce Triglycerides	AQ
17/08	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides	BU
04/08	Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results	BU
04/08	Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher	BU
03/08	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	BU
27/07	Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	BU
22/07	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia	BU
21/07	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results	BU
23/06	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome	AQ
22/06	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)	BU
18/06	Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars	BU
02/06	Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events	BU
27/05	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	BU
26/05	Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress	BU
14/05	Arrowhead Pharmaceuticals : ECO 2026 LBP4078 Kerr Activin E Poster 6May2026 FINAL	PU
13/05	Arrowhead Pharmaceuticals : TIDES 2026 KM final (1)	PU
08/05	Arrowhead Pharmaceuticals : ARWR FQ2 2026 Script FINAL	PU
07/05	Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results	BU
05/05	Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals	BU